BPC-157
Body Protection Compound-157
BPC-157 is a peptide people usually talk about for Ulcerative colitis and Inflammatory bowel disease. It is still in the FDA review process, so people are watching both the research and the access question closely.
Why does this matter?
BPC-157 matters because a lot of people hear about it online without a clear sense of what it may actually help with. This page gives you the plain-English version first, then shows where the research is strongest, what is still uncertain, and where the peptide stands in the FDA review process.
Molecular weight
1419.53 g/mol
Molecular formula
C₆₂H₉₈N₁₆O₂₂
Amino acid count
15
Review date
July 23-24, 2026
Sequence / structure
Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
Other names
Body Protection Compound-157, Bepecin, PL 14736, PL-10, BPC 157, BPC-15, Gastric pentadecapeptide BPC 157
Status
Under FDA review for ulcerative colitis
BPC-157 is a gut-derived healing peptide best known for helping damaged tissue recover faster. It shows up most in conversations about tendon injuries, muscle strains, ligament repair, and digestive support because it appears to calm inflammation while speeding up repair. One reason people keep coming back to it is that it is unusually stable in the digestive tract, which makes oral use part of the conversation in a way that is rare for peptides.
The quick version before the deep dive
- •People usually talk about BPC-157 for Ulcerative colitis and Inflammatory bowel disease.
- •Inflammatory bowel disease (IBD).
- •Helps regulate NO synthesis, promoting better blood flow and blood flow to injured tissues.
- •Upregulates VEGF (vascular endothelial growth factor), promoting new blood vessel formation.
Deep Dive: Mechanism of Action +
Nitric Oxide System — Modulates NO synthesis, promoting vasodilation and blood flow to injured tissues
Angiogenesis — Upregulates VEGF (vascular endothelial growth factor), promoting new blood vessel formation
Growth Factor Modulation — Increases EGF, FGF, and their receptor expression in damaged tissue
FAK-Paxillin Pathway — Activates focal adhesion kinase signaling, promoting cell migration and tissue repair
Anti-inflammatory — Reduces pro-inflammatory cytokines (TNF-α, IL-6), blocks oxidative stress
Collagen Synthesis — Enhances collagen deposition and organization in healing tendons/ligaments
Dopaminergic System — Modulates dopamine system (relevant to gut-brain axis and neuroprotection)
GABAergic System — Interacts with GABA receptors (relevant to its anxiolytic-like effects)
Cytoprotection — Protects endothelial cells, maintains GI mucosal integrity
Where people usually see it discussed
Gastrointestinal +
- Ulcerative colitis (primary FDA review indication)
- Inflammatory bowel disease (IBD)
- Gastric ulcers and esophageal lesions
- Intestinal fistulas
- Short bowel syndrome
- NSAID-induced gastropathy
- Leaky gut / intestinal permeability
Musculoskeletal +
- Tendon healing (Achilles, rotator cuff, patellar)
- Ligament repair
- Muscle tears and strains
- Bone fracture healing
- Joint inflammation
Neurological +
- Peripheral nerve repair
- Traumatic brain injury
- Spinal cord injury
- Dopaminergic system protection
- Alcohol/drug-induced neurotoxicity
Other +
- Wound healing (surgical, burns, diabetic)
- Periodontal disease
- Organ protection (liver, kidney, heart)
- Corneal healing
Formal evidence and study snapshots
Deep Dive: Clinical Trials +
PL 14736 Phase II (Planiva)
Completed (~2005)IBD/Ulcerative Colitis
Oral tablet formulation; showed promising results in UC
NCT identifier not public
Preclinical/Early PhaseWound Healing
Multiple animal model publications
University of Zagreb studies
OngoingMultiple indications
30+ years of continuous research
What the current safety discussion looks like
- ✓No LD50 achievable — In toxicology studies, researchers could not establish a lethal dose in animal models, even at doses vastly exceeding therapeutic ranges
- ✓No reported organ toxicity in chronic dosing studies
- ✓No mutagenic activity demonstrated
- ✓No teratogenic effects observed in reproductive studies
- ✓Side effects (anecdotal): Mild nausea, lightheadedness, injection site irritation (rare)
- ✓Drug interactions: Limited data; theoretical interaction with anticoagulants due to angiogenic properties
- ✓Contraindications (theoretical): Active malignancy (due to angiogenic/growth factor properties), pregnancy
How the status timeline currently reads
Pre-2023
Category 1 — eligible for 503A compounding
September 2023
Moved to Category 2 by FDA
February 27, 2026
RFK Jr. announces intent to reclassify on Joe Rogan Experience
April 16, 2026
FDA formally announces PCAC meeting
July 23-24, 2026
Advisory committee to review for 503A Bulks List (ulcerative colitis indication)
Post-meeting
If recommended → formal rulemaking to add to 503A Bulks List
How dosing is usually described
Subcutaneous Injection
Systemic healing: 250-500 mcg/day Localized injury: 250-750 mcg injected near injury site Duration: Typically 4-12 weeks
Oral Administration
GI conditions: 250-500 mcg/day (unique oral stability) Capsule formulations reported in clinical research
Intramuscular
Muscle/tendon injuries: 250-500 mcg near affected area
Routes of Administration
Subcutaneous (most common) Oral (uniquely stable in gastric acid) Intramuscular Topical (experimental) Intraperitoneal (research only)
Research protocols only. Not medical advice.
The citations behind the page
Deep Dive: Key Research Papers +
- 1
Sikirić P, et al.*. "Pentadecapeptide BPC 157 and its effects on a NSAID toxicity model." Life Sciences 1994.
- 2
Sikirić P, et al.*. "Brain-gut axis and pentadecapeptide BPC 157: Theoretical and practical implications." Current Neuropharmacology 2016.
- 3
Chang CH, et al.*. "BPC 157 promotes muscle regeneration by triggering M2 macrophage polarization." Journal of Orthopaedic Research 2020.
- 4
Staresinic M, et al.*. "Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon." Journal of Orthopaedic Research 2003.
- 5
Seiwerth S, et al.*. "BPC 157's effect on healing." Journal of Physiology-Paris 2014.
- 6
Vukojevic J, et al.*. "Pentadecapeptide BPC 157 and the central nervous system." Neural Regeneration Research 2022.
- 7
Sikirić P, et al.*. "Stable gastric pentadecapeptide BPC 157—NO-system relation." Current Pharmaceutical Design 2014.
- 8
Tkalčević VI, et al.*. "Enhancement by PL 14736 of granulation and collagen organization in healing wounds." Journal of Pharmacology and Experimental Therapeutics 2007.
- 9
Cesarec V, et al.*. "Pentadecapeptide BPC 157 and the esophagocutaneous fistula healing therapy." European Journal of Pharmacology 2013.
- 10
Klicek R, et al.*. "Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon-anastomosis." Journal of Physiology and Pharmacology 2013.
Common questions about BPC-157
What is BPC-157? +
BPC-157 is Body Protection Compound-157, one of the peptides currently under review in connection with ulcerative colitis.
What is BPC-157 being reviewed for? +
The current advisory review focuses on ulcerative colitis, with a listed review date of July 23-24, 2026.
Which category does BPC-157 belong to? +
BPC-157 is grouped in this library under Healing.
How many amino acids are in BPC-157? +
BPC-157 is presented here as a 15-amino-acid peptide or peptide analog based on the source research and naming conventions.
What is the sequence or structure note for BPC-157? +
Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val.
What research applications are most associated with BPC-157? +
Ulcerative colitis, Inflammatory bowel disease, Gastric ulcers and esophageal lesions, and Intestinal fistulas
How is BPC-157 described as working in the current research? +
Helps regulate NO synthesis, promoting better blood flow and blood flow to injured tissues. Upregulates VEGF (vascular endothelial growth factor), promoting new blood vessel formation.
How is BPC-157 usually discussed in protocols or treatment plans? +
BPC-157 is most often described with under-the-skin injection and oral use protocols in the source material.
What does the safety discussion say about BPC-157? +
No LD50 achievable — In toxicology studies, researchers could not establish a lethal dose in animal models, even at doses vastly exceeding therapeutic ranges No reported organ toxicity in chronic dosing studies
Continue the comparison
KPV
KPV is a peptide people usually talk about for Inflammatory bowel disease and Intestinal inflammation. It is still in the FDA review process, so people are watching both the research and the access question closely.
TB-500
TB-500 is a peptide people usually talk about for Chronic non-healing wounds and Surgical wound healing. It is still in the FDA review process, so people are watching both the research and the access question closely.
GHK-Cu
GHK-Cu is a peptide people usually talk about for Skin Rejuvenation: Improves skin elasticity, firmness, and thickness while reducing wrinkles, hyperpigmentation, and photodamage. and Wound Healing: Accelerates the healing of chronic wounds, surgical incisions, and burns by promoting tissue remodeling and angiogenesis.. It is still in the FDA review process, so people are watching both the research and the access question closely.
Get notified when BPC-157 becomes available
Join the waitlist for peptide-specific updates, regulatory milestones, and access news connected to the GobyMeds care pathway.